{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:47:24Z","timestamp":1793159244558,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jacc.2019.11.056","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T13:58:50Z","timestamp":1581343130000},"page":"578-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy"],"prefix":"10.1016","volume":"75","author":[{"given":"Usman","family":"Baber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Urooj","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin\u00e9s","family":"Escolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapoorna S.","family":"Kini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.11.056_bib1","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.056_bib2","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.101.24.2823","article-title":"Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans","volume":"101","author":"Cadroy","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.056_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.056_bib4","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib5","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib7","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet Inhibition and Patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2019.11.056_bib9","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.056_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib11","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.056_bib12","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.056_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2019.11.056_bib14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1161\/01.CIR.0000142296.19558.99","article-title":"Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex\u00a0vivo model","volume":"110","author":"Vilahur","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.056_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1160\/TH06-12-0732","article-title":"A\u00a0novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models","volume":"97","author":"Wang","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.RES.70.1.39","article-title":"ADP plays an important role in mediating platelet aggregation and cyclic flow variations in\u00a0vivo in stenosed and endothelium-injured canine coronary arteries","volume":"70","author":"Yao","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2019.11.056_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.11.056_bib18","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0735-1097(99)00018-2","article-title":"Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile","volume":"33","author":"Dangas","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1160\/TH17-04-0277","article-title":"Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease","volume":"117","author":"Zafar","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib20","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/01.ATV.18.8.1342","article-title":"Administration of abciximab during percutaneous coronary intervention reduces both ex\u00a0vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab","volume":"18","author":"Dangas","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.11.056_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4939-8597-5_12","article-title":"Badimon perfusion chamber: an ex\u00a0vivo model of thrombosis","volume":"1816","author":"Zafar","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jacc.2019.11.056_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1160\/th14-03-0269","article-title":"Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin","volume":"112","author":"Zafar","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1160\/TH13-10-0874","article-title":"A\u00a0comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity: results of the ISAR-HPR registry","volume":"112","author":"Mayer","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1160\/TH05-10-0700","article-title":"Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex\u00a0vivo human study","volume":"95","author":"Lev","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/cvr\/cvy227","article-title":"Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis","volume":"115","author":"Wilson","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2019.11.056_bib26","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jacc.2003.09.060","article-title":"Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation","volume":"43","author":"Lev","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.056_bib27","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.11.056_bib28","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.11.056_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib30","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2011.04453.x","article-title":"Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel","volume":"9","author":"Kirkby","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib31","article-title":"Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT Study","author":"Franchi","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.11.056_bib32","first-page":"763","article-title":"Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus treated with dual antiplatelet therapy: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-5 study","volume":"4","author":"Franchi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719386930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719386930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:30:04Z","timestamp":1760016604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719386930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0735109719386930"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.056","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}